Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Metabolomic dynamics of cytokine release syndrome in CD19 CAR-T therapy

Zhouning Lin, Tingting Yang, Mingming Zhang, Shan Fu, Meng Zhang, Zhong Zheng Zheng, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 7663.

https://doi.org/10.1182/blood-2025-7663

Published: 2025

Journal Articles

Pre-treatment ZNF683⁺ effector CD8⁺ T cells predict response to BiTE therapy in acute lymphoblastic leukemia: Insights from single-cell and TCR sequencing

Linghui Zhou, Cheng Zu, Kexin Wang, Mingming Zhang, Shan Fu, Jingjing Feng, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 5086.

https://doi.org/10.1182/blood-2025-5086

Published: 2025

Journal Articles

Ultra-low-dose IL-10-expressing CAR-T cells achieve high efficacy in R/R DLBCL: An update analysis

Blood (2025) 146 (Supplement 1): 2395.

https://doi.org/10.1182/blood-2025-2395

Published: 2025

Journal Articles

OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study

Yongxian Hu, Mingming Zhang, Yajing Zhang, Shan Fu, Jingjing Feng, Guoai Su, Dan Song, Chia-Wei Chang, Hongmei Wang, Sihui Guan, He Huang

Blood (2025) 146 (Supplement 1): 2387.

https://doi.org/10.1182/blood-2025-2387

Published: 2025

Journal Articles

Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies

Tingting Yang, Mingming Zhang, Mengqi Yu, Shan Fu, Jingjing Feng, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Zhang, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 1040.

https://doi.org/10.1182/blood-2025-1040

Published: 2025

Journal Articles

Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma

Mingming Zhang, Lianxuan Liu, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Zhang, He Huang

Blood (2025) 146 (Supplement 1): 1940.

https://doi.org/10.1182/blood-2025-1940

Published: 2025

Journal Articles

Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS

Junqing Wu, Xueping Luo, Xiaoyu Liu, Jingwen Li, Shan Fu, He Huang, Weiyan Zheng

Blood (2025) 146 (Supplement 1): 3449.

https://doi.org/10.1182/blood-2025-3449

Published: 2025

Journal Articles

Baseline PET-CT in predicting CRS and survival outcomes of R/R MM patients following CAR T-cell therapy

Pingnan Xiao, Xin Zhao, Linqin Wang, Yixue Li, Mingming Zhang, Jingjing Feng, Shan Fu, Houli Zhao, Kui zhao, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 5855.

https://doi.org/10.1182/blood-2025-5855

Published: 2025

Journal Articles

Donor-derived secondary CAR-T cell therapy for relapsed leukemia following initial CAR-T bridged to allogeneic transplantation: Efficacy and safety analysis

Yiqing Ren, Weiming Zhang, Guoqing Wei, Mingming Zhang, Shan Fu, Jingjing Feng, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 5941.

https://doi.org/10.1182/blood-2025-5941

Published: 2025

Journal Articles

CD7-negative T cell immune reconstitution after CD7-targted CAR-T cell therapy

Haiqiong Zheng, Houli Zhao, Xin Jin, Delin Kong, Ruirui Jing, Jiazhen Cui, Simao Huang, Mingming Zhang, Jingjing Feng, Shan Fu, Guoqing Wei, Alex H Chang, Dongrui Wang, Yongxian Hu, He Huang

Blood (2025) 146 (Supplement 1): 5900.

https://doi.org/10.1182/blood-2025-5900

Published: 2025

Journal Articles

One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus

Jingjing Feng, Heng Cao, Mingming Zhang, Xintong Feng, Shan Fu, Guoqing Wei, Ruimin Hong, Lianjun Shen, Jin Lin, Zhihong Liu, Jia Liu, Yongxian Hu, He Huang

Blood (2025) 146 (Supplement 1): 2384.

https://doi.org/10.1182/blood-2025-2384

Published: 2025

Journal Articles

Immune remodeling enables sustained EBV clearance in B-cell and plasma cell malignancies after anti-CD19/BCMA CAR-T therapy: A post-hoc analysis

Shuyang Wang, Qisan Wu, Mengmeng Huang, Mingming Zhang, Shan Fu, Tingting Yang, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Zhang, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 2381.

https://doi.org/10.1182/blood-2025-2381

Published: 2025

Journal Articles

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

Blood (2024) 144 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2024-209418

Published: 2024

Journal Articles

1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust in vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Yongxian Hu, Mingming Zhang, Shan Fu, Ruimin Hong, Jiazhen Cui, Simao Huang, Min Gao, Daojun Bai, Jingjing Ren, Xingbing Wang, Yugang Guo, Li Tang, He Huang

Blood (2024) 144 (Supplement 1): 2074.

https://doi.org/10.1182/blood-2024-207694

Published: 2024

Journal Articles

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Tingting Yang, Yetian Dong, Mingming Zhang, Jingjing Feng, Shan Fu, Pingnan Xiao, Ruimin Hong, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu

Blood (2024) 144 (Supplement 1): 2818.

https://doi.org/10.1182/blood-2024-210124

Published: 2024

Journal Articles

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

Mingming Zhang, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Chang, He Huang

Blood (2024) 144 (Supplement 1): 91.

https://doi.org/10.1182/blood-2024-210462

Published: 2024

Journal Articles

APRIL CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial

Wenxiao Li, Yongxian Hu, Mingming Zhang, Xinyi Lai, Mengyu Zhao, Shan Fu, Ruimin Hong, Alex H. Chang, He Huang

Blood (2024) 144 (Supplement 1): 7229.

https://doi.org/10.1182/blood-2024-209660

Published: 2024

Journal Articles

A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial

Yongxian Hu, Yali Zhou, Mingming Zhang, Shan Fu, Yong Yu, Ming Gao, Ruimin Hong, Houli Zhao, Lu Han, Jiangtao Ren, He Huang

Blood (2024) 144 (Supplement 1): 921.

https://doi.org/10.1182/blood-2024-207322

Published: 2024

Journal Articles

Prior ASCT Has a Negative Impact on Outcomes in Relapsed/Refractory Multiple Myeloma Patients after BCMA CAR-T Therapy

Chunxiang Jin, Rongrong Chen, Shan Fu, Alex H. Chang, He Huang, Yongxian Hu

Blood (2024) 144 (Supplement 1): 7082.

https://doi.org/10.1182/blood-2024-201470

Published: 2024

Journal Articles

Prognostic Risk Factors for Patients with Candida Tropicalis Fungemia Infections and Hematological Malignancies

Haisu Zhao, Shan Fu, Yuanyuan Zhu, He Huang, Weiyan Zheng

Blood (2023) 142 (Supplement 1): 5846.

https://doi.org/10.1182/blood-2023-189437

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Metabolomic dynamics of cytokine release syndrome in CD19 CAR-T therapy

Pre-treatment ZNF683⁺ effector CD8⁺ T cells predict response to BiTE therapy in acute lymphoblastic leukemia: Insights from single-cell and TCR sequencing

Ultra-low-dose IL-10-expressing CAR-T cells achieve high efficacy in R/R DLBCL: An update analysis

OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study

Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies

Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma

Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS

Baseline PET-CT in predicting CRS and survival outcomes of R/R MM patients following CAR T-cell therapy

Donor-derived secondary CAR-T cell therapy for relapsed leukemia following initial CAR-T bridged to allogeneic transplantation: Efficacy and safety analysis

CD7-negative T cell immune reconstitution after CD7-targted CAR-T cell therapy

One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus

Immune remodeling enables sustained EBV clearance in B-cell and plasma cell malignancies after anti-CD19/BCMA CAR-T therapy: A post-hoc analysis

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust in vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

APRIL CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial

A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial

Prior ASCT Has a Negative Impact on Outcomes in Relapsed/Refractory Multiple Myeloma Patients after BCMA CAR-T Therapy

Prognostic Risk Factors for Patients with Candida Tropicalis Fungemia Infections and Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only